Case Reports and Reviews

Review Article

Hormonal Imbalances and Obsessive-Compulsive Disorder

Eda Gorbis, Alexander Gorbis, Amanda Rudolph, Aanya Jajoo

The Westwood Institute for Anxiety Disorders, Los Angeles, CA

Abstract

Obsessive-compulsive disorder (OCD) is a chronic mental health condition marked by intrusive thoughts and repetitive behaviors, significantly impairing daily functioning. This paper investigates the relationship between hormonal imbalances and OCD by reviewing existing literature and presenting detailed case studies. The analysis focuses on the impact of hormonal fluctuations, particularly involving estrogen, androgens, progesterone, melatonin, and cortisol, on the onset and severity of OCD symptoms. Case studies of individuals with polycystic ovary syndrome (PCOS), postpartum hormonal changes, and post-hysterectomy hormonal shifts illustrate how hormonal imbalances can exacerbate OCD symptoms. The findings indicate that hormonal events, such as premenstrual periods and pregnancy, can trigger or worsen OCD symptoms in approximately 30% of women. Hormone replacement therapy and targeted hormonal interventions show promise in alleviating OCD symptoms, suggesting a potential for hormone-based treatment approaches. This study underscores the need for a comprehensive understanding of hormonal influences in managing OCD to enhance treatment outcomes and improve patients' quality of life.

Correspondence

Dr. Eda Gorbis

The Westwood Institute for Anxiety Disorders, 921 Westwood Blvd., Suite 223, Los Angeles, California 90024, United States.

Email: thewestwoodinstitute@gmail.com

- Received Date: 05 Aug 2024
- Accepted Date: 25 Aug 2024
- Publication Date: 29 Aug 2024

Introduction

Obsessive-compulsive disorder (OCD) is a chronic mental health condition defined by the presence of obsessions and/or compulsions. According to the DSM-V, obsessions are recurrent, persistent thoughts, impulses, or images that cause significant anxiety or distress. Compulsions are repetitive behaviors or mental acts performed in response to obsessions or according to rigid rules.

OCD affects approximately 1-2% of the population globally. The disorder can significantly impair daily functioning, leading to distress and reduced quality of life. Individuals with OCD often experience social, occupational, and academic difficulties. Risk factors for OCD include genetic predisposition, neurobiological abnormalities, and environmental stressors. Family history, serotonin dysregulation, and autoimmune responses are among the biological factors implicated in OCD. Environmental factors, such as trauma and significant life changes, can also trigger or exacerbate symptoms.

This analysis aims to examine the role of hormonal imbalances in the development and exacerbation of OCD symptoms. By assessing literature and presenting case studies, the paper seeks to provide a comprehensive understanding of how hormonal fluctuations influence OCD and explore potential treatment approaches. Hormonal imbalances play a significant role in the onset and severity of OCD and addressing these imbalances can lead to improved treatment outcomes for individuals with OCD.

Literature Review

Obsessive-Compulsive Disorder: Definition and Manifestation

Obsessions, as defined by the DSM-V, are intrusive, unwanted thoughts, impulses, or images that cause significant anxiety or distress. Characteristics of obsessions include their recurrent nature and the individual's recognition of these thoughts as products of their own mind. Common obsessions include contamination, harm, symmetry, aggressive themes, sexual themes, scrupulosity, forbidden thoughts, and the need to tell or confess.

Compulsions are repetitive behaviors or mental acts performed in response to obsessions. These actions are aimed at reducing distress or preventing a feared event, often becoming excessive and unrelated to the actual threat. Common compulsions include washing, checking, counting, repeating, touching, ordering, hoarding, and praying.

OCD is distinguished from other anxiety disorders by its specific symptomatology and diagnostic criteria. It is differentiated

Citation: Gorbis E, Gorbis A, Rudolph A, Jajoo A. Hormonal Imbalances and Obsessive-Compulsive Disorder. Case Rep Rev. 2024;4(1):42

from generalized anxiety disorder (GAD), body dysmorphic disorder (BDD), and Tourette's syndrome through careful clinical assessment.

Risk Factors for OCD

Genetic/Biological Factors

OCD has a notable genetic component, as evidenced by higher prevalence rates among first-degree relatives of individuals with the disorder. Twin studies further support this genetic link, showing a 70% concordance rate for OCD among identical twins compared to 50% among fraternal twins. This indicates that genetic factors play a significant role in the development of OCD.

Neuroimaging studies have identified abnormalities in specific brain regions associated with OCD. These include the frontal lobes, which are involved in planning, executive functioning, and organizing behaviors; the basal ganglia, which are involved in routine behaviors like grooming; and the cingulum, which assists in communicating the brain's behavioral and emotional messages. These abnormalities suggest that structural and functional brain differences contribute to OCD symptoms.

One of the most well-established biological theories of OCD is the serotonin hypothesis. This theory posits that OCD is linked to abnormally low levels of the neurotransmitter serotonin. Serotonin is crucial for regulating mood, anxiety, and other psychiatric functions. Its deficiency is not only associated with OCD but also with anxiety, depression, and other psychiatric disorders.

In some susceptible children, autoimmune responses to streptococcal infections can trigger OCD symptoms. This phenomenon, known as pediatric autoimmune neuropsychiatric disorders, associated with streptococcal infections (PANDAS), highlights the role of immune system dysregulation in the onset of OCD.

Environmental Stressors

Various environmental stressors can trigger or exacerbate OCD symptoms. These include physical, emotional, or sexual abuse, changes in living situations, chronic or severe illness in oneself or a loved one, job loss, job changes, or significant work-related stress, marital issues, breakups, or family conflicts, or even academic pressure, bullying, or transitions to new schools.

Stressful life events can act as triggers for the onset of OCD or worsen existing symptoms. The relationship between stress and OCD suggests that managing stress through therapeutic interventions could be beneficial for individuals with OCD.

Hormonal Imbalances

Hormonal imbalances are increasingly recognized as significant factors in OCD. Hormonal fluctuations can influence mood, anxiety levels, and stress responses, thereby impacting OCD symptoms. Specific hormonal events and imbalances that play crucial roles in OCD pathophysiology include those involving estrogn, androgens, progesterone, melatonin, and cortisol.

OCD symptoms often worsen during premenstrual periods when estrogen levels are highest. Furthermore, fluctuating hormones during pregnancy and postpartum periods can trigger OCD symptoms. Approximately 30% of women observed during pregnancy report the onset or worsening of OCD symptoms. Specific hormonal events and imbalances, such as those involving estrogen, androgens, progesterone, melatonin, and cortisol, play crucial roles in OCD pathophysiology.

The Role of Hormones in OCD Pathophysiology

Gonadal Hormones

Estrogen is a key hormone in the regulation of mood and anxiety. It has neuroprotective effects and plays a critical role in maintaining emotional stability. However, its role in OCD is complex. While estrogen can protect against anxiety under normal conditions, imbalances in estrogen levels can exacerbate OCD symptoms. For instance, fluctuations in estrogen levels during the menstrual cycle, pregnancy, and postpartum periods have been linked to the worsening of OCD symptoms in women. These fluctuations can lead to increased anxiety and intrusive thoughts, contributing to the severity of OCD.

Androgens, including testosterone, are typically associated with male physiology but are present in both sexes. Elevated androgenic activity has been implicated in OCD, particularly in men. Studies suggest that increased levels of testosterone may correlate with the severity of OCD symptoms. Antiandrogenic therapy, which reduces the levels of sex hormones, has shown promise in treating OCD symptoms linked to high androgen levels. This therapy helps in mitigating obsessive-compulsive behaviors by balancing the hormonal environment.

Progesterone is another crucial hormone that influences mood and anxiety. It has calming effects on the brain and helps in regulating anxiety and seizure activities. A deficiency in progesterone can lead to increased anxiety and exacerbate OCD symptoms. Progesterone levels naturally fluctuate during the menstrual cycle and can drop significantly during the postpartum period, contributing to the onset or worsening of OCD. Hormone replacement therapy that includes progesterone can help in stabilizing these levels and reducing OCD symptoms.

Other Hormonal Factors

Melatonin, produced by the pineal gland, is essential for regulating sleep-wake cycles. It induces sleep and has been found to be deficient in many OCD patients. Adequate sleep is crucial for mental health, and a deficiency in melatonin can lead to sleep disturbances, which in turn can exacerbate OCD symptoms. Addressing melatonin deficiency through supplementation can help improve sleep quality and potentially reduce the severity of OCD symptoms.

Cortisol is known as the stress hormone, released in response to stress and playing a vital role in the body's fight-or-flight response. In individuals with OCD, cortisol levels are often elevated, reflecting a heightened state of stress and anxiety. Chronic elevation of cortisol can lead to various adverse effects on physical and mental health, including the exacerbation of OCD symptoms. Managing stress and reducing cortisol levels through lifestyle changes, therapy, and possibly medication can help in alleviating OCD symptoms.

Hypothalamic-Pituitary-Gonadal (HPG) Axis

The hypothalamic-pituitary-gonadal (HPG) axis is a complex system that regulates the production of reproductive and stress hormones. It involves the hypothalamus, pituitary gland, and gonads (ovaries and testes), which work together to maintain hormonal balance. The HPG axis controls the release of hormones that are critical for reproductive health and stress response. The hypothalamus releases gonadotropin-releasing hormone (GnRH), which signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone

(FSH). These hormones then stimulate the gonads to produce sex hormones such as estrogen, progesterone, and testosterone.

Disruptions in the HPG axis can lead to imbalances in these hormones, significantly impacting OCD symptoms. For instance, during periods of hormonal transition such as puberty, pregnancy, or menopause, the HPG axis undergoes significant changes that can exacerbate OCD. Understanding the functioning of the HPG axis and its influence on hormone levels is crucial for developing effective treatment strategies for OCD that consider hormonal imbalances.

Postpartum OCD

Postpartum OCD is a specific manifestation of OCD that occurs during the postpartum period. It is characterized by obsessions and compulsions related to the well-being of the newborn. Hormonal changes during this period, particularly the drastic drop in estrogen and progesterone levels after childbirth, are thought to trigger or worsen OCD symptoms. Postpartum OCD typically emerges or intensifies within the first four to six weeks after giving birth. Women with postpartum OCD experience intrusive thoughts about harming their baby, contamination fears, and excessive concerns about the baby's safety. These obsessions lead to compulsive behaviors such as constant checking on the baby, excessive washing, and seeking reassurance from others.

The obsessions in postpartum OCD are often centered around fears of harming the baby, being an inadequate parent, and the baby's safety. Compulsions are aimed at neutralizing these fears and often include behaviors like repeatedly washing the baby, incessantly checking on the baby, and avoiding certain activities that might "harm" the baby.

Understanding the hormonal underpinnings of postpartum OCD is crucial for developing targeted treatment strategies. Hormone replacement therapy, cognitive-behavioral therapy (CBT), and selective serotonin reuptake inhibitors (SSRIs) are potential treatment options that can help manage symptoms by addressing both hormonal and psychological factors.

Methodology

A case study approach was utilized to delve into the intricate relationship between hormonal imbalances and OCD symptoms. This method involves an in-depth examination of individual cases, allowing for a comprehensive understanding of how hormonal fluctuations influence OCD. By focusing on specific instances, researchers can gather detailed qualitative data and draw meaningful connections between hormonal changes and the manifestation or exacerbation of OCD symptoms. Each case provides a unique perspective, contributing to the overall understanding of the role of hormones in OCD pathophysiology.

The selection of case studies was based on the presence of clinically diagnosed OCD symptoms along with documented hormonal imbalances. The inclusion criteria ensured that the cases represented a diverse range of hormonal issues, including polycystic ovary syndrome (PCOS), postpartum hormonal changes, and hormonal shifts post-hysterectomy. Patients were selected to cover various age groups and backgrounds to provide a comprehensive view of how different hormonal contexts affect OCD. Additionally, the severity and chronicity of OCD symptoms, along with the type and extent of hormonal imbalance, were considered to ensure a varied sample that could highlight different aspects of the relationship between hormones and OCD.

To quantify the severity of OCD symptoms and assess the impact of treatment, a variety of validated assessment tools were employed. These tools included the Yale-Brown Obsessive-Compulsive Scale (YBOCS), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), Fixity of Beliefs, Brown Assessment of Beliefs Scale (BABS), NIMH-Global, Global Assessment Scale (GAS), Obsessive-Compulsive Inventory - Short Version (OCI-SV), Obsessive-Compulsive Disorder Not Otherwise Specified (OCON), Fear Survey Schedule, and Willoughby Questionnaire. Each of these tools was selected for its reliability and validity in measuring specific constructs related to OCD, anxiety, depression, and overall functioning.

Data analysis

The data collected from the assessment tools were systematically analyzed to evaluate the effectiveness of hormonal interventions. Pre-treatment scores provided a baseline, and post-treatment scores were used to assess improvements or changes in symptoms. Statistical analyses, such as paired t-tests or ANOVA, were conducted to determine the significance of the changes observed. This quantitative analysis helped in understanding the impact of hormone therapy on OCD, anxiety, and depression symptoms. Additionally, qualitative data from patient interviews and clinical observations were used to contextualize the numerical findings and provide a richer understanding of the treatment outcomes.

Treatment approaches

The treatment approaches for each case were tailored to address specific hormonal imbalances and associated OCD symptoms. The primary interventions included Hormone Replacement Therapy (HRT), Psychotherapy and Pharmacotherapy. HRT was used to correct hormonal deficiencies or imbalances. For instance, estrogen and progesterone therapies were administered to women with PCOS or postpartum hormonal changes, while testosterone was supplemented for men with androgenetic issues. Psychotherapy focused on cognitive-behavioral therapy (CBT) to address OCD symptoms directly. This involved exposure and response prevention (ERP) techniques to help patients manage their obsessions and compulsions. Pharmacotherapy included medications such as selective serotonin reuptake inhibitors (SSRIs) to manage OCD and related anxiety or depressive symptoms. The choice of medication was guided by the patient's hormonal profile and overall health condition. The combination of these approaches was intended to provide a holistic treatment plan, addressing both the psychological and physiological aspects of OCD.

Case Studies

Case #1: 25-Year-Old Female with Hyperandrogenism

This case study focuses on a 25-year-old female diagnosed with PCOS, who presented with severe adult acne and a cyclical worsening of her obsessive-compulsive disorder (OCD) symptoms. The patient's obsessions were diverse, including concerns about perfectionism, fears related to homosexuality, masturbation, moralistic issues, scrupulosity, fear of death by choking, and incest. Additionally, she experienced magical fears of sending notes or messages to an arbitrary source that could potentially harm a member of her family, religious fears, and scrupulosity and morality concerns regarding right and wrong. Her compulsions were characterized by a strong need to

confess, seek reassurance, and avoid certain foods and places. She also engaged in excessive checking for reassurance and avoided general areas she interpreted as danger zones, fearing that a note she sent might lead someone to harm her loved ones.

The treatment plan for this patient included metformin, which is commonly used to manage insulin resistance in PCOS, along with hormone therapies using transdermal estradiol and vaginal progesterone. These treatments aimed to address her hormonal imbalances and alleviate her OCD symptoms.

Following the treatment, the patient reported a notable reduction in depression, a significant improvement in her acne, weight loss, and a decrease in both obsessions and compulsions. The pre- and post-treatment data analysis revealed substantial improvements across various scales. The Yale-Brown Obsessive-Compulsive Scale (YBOCS) score was reduced from 36 to 8, indicating a significant decrease in the severity of her OCD symptoms. The Hamilton Anxiety Rating Scale (HAM-A) score decreased from 19 to 1, reflecting a marked reduction in anxiety levels. Similarly, the Hamilton Depression Rating Scale (HAM-D) score dropped from 27 to 6, showing significant alleviation of depressive symptoms. The Fixity of Beliefs score decreased from 6 to 3, indicating less rigidity in obsessive beliefs. The Brown Assessment of Beliefs Scale (BABS) improved from 10 to 2, suggesting better insight into her obsessive thoughts. The NIMH-Global assessment scores improved from 10-12 to 1-3, reflecting overall psychiatric improvement. The Global Assessment Scale (GAS) scores increased from 31-21 to 80-71, demonstrating enhanced overall functioning. The Obsessive-Compulsive Inventory - Short Version (OCI-SV) scores were reduced from 28 to 8, indicating fewer distressing obsessive-compulsive symptoms. The Obsessive-Compulsive Disorder Not Otherwise Specified (OCON) frequency/distress scores dropped from 42/44 to 11/12, showing significant improvement in OCD severity and distress. The Fear Survey Schedule scores decreased from 165 to 54, indicating a substantial reduction in fear responses. Lastly, the Willoughby Questionnaire scores improved from 49 to 13, demonstrating better stress coping mechanisms.

Case #2: 33-Year-Old Female with Eating Disorder and OCD

In this case study, a 33-year-old female patient presented with polycystic ovary disease (PCOD), insulin resistance, severe OCD, and migraines that were closely related to her menstrual cycle. The patient's OCD symptoms were severe and exacerbated by her hormonal fluctuations during menses. Her obsessions included perfectionistic concerns, intense fears of pedophilia and molestation, sexual fears, forbidden sexual thoughts, and scrupulosity. These obsessions drove her to engage in compulsions such as seeking reassurance, performing mental rituals, and avoiding certain situations and stimuli.

To address these complex symptoms, the patient underwent a treatment plan that included hormone therapy and psychotherapy. The hormone therapy aimed to regulate her hormonal imbalances, particularly those linked to her menstrual cycle and PCOD, while psychotherapy focused on cognitive-behavioral techniques to manage and reduce her OCD symptoms.

The pre- and post-treatment data analysis revealed substantial improvements across several standardized scales used to measure OCD, anxiety, and depression. The Yale-Brown Obsessive-Compulsive Scale (YBOCS) score was reduced from 36 to 12, indicating a significant decrease in the severity of her OCD symptoms. The Hamilton Anxiety Rating Scale (HAM-A) score decreased from 20 to 8, reflecting a marked reduction in anxiety levels. The Hamilton Depression Rating Scale (HAM-D) score showed a decrease from 19 to 16, indicating alleviation of depressive symptoms. The Fixity of Beliefs score decreased from 13 to 7, indicating less rigidity in obsessive beliefs. The Brown Assessment of Beliefs Scale (BABS) improved from 9 to 5, suggesting better insight into her obsessive thoughts. The NIMH-Global assessment scores improved from 10-12 to 6-8, reflecting overall psychiatric improvement. The Global Assessment Scale (GAS) scores increased from 40-31 to 80-71, demonstrating enhanced overall functioning. The Obsessive-Compulsive Inventory - Short Version (OCI-SV) scores were reduced from 29 to 11, indicating fewer distressing obsessive-compulsive symptoms. The Obsessive-Compulsive Disorder Not Otherwise Specified (OCON) frequency/distress scores dropped from 81/83 to 23/24, showing significant improvement in OCD severity and distress. The Fear Survey Schedule scores decreased from 114 to 31, indicating a substantial reduction in fear responses. Lastly, the Willoughby Questionnaire scores improved from 40 to 31, demonstrating better stress coping mechanisms.

Case #3: 53-Year-Old Female with Post-Hysterectomy OCD

This case study involves a 53-year-old female who developed severe OCD following a hysterectomy and bilateral oophorectomy performed to treat intractable migraines. The sudden onset of OCD symptoms post-surgery was severe enough to render her homebound. Over the next 14 years, she struggled with intense OCD symptoms that significantly impaired her daily functioning and quality of life. Her obsessions were characterized by magical fears of sending notes or messages to an arbitrary source that could potentially harm a member of her family, religious fears, and scrupulosity with intense concerns about morality and right versus wrong. These obsessions led to compulsions including excessive checking for reassurance and avoidance of general areas interpreted as danger zones, where she feared that a note she sent might be found and acted upon, leading to harm to her loved ones.

To address her hormonal deficiencies and severe OCD symptoms, the treatment plan included hormone replacement therapy using subcutaneous estradiol and testosterone pellets. These hormone therapies aimed to stabilize her hormonal levels post-hysterectomy and mitigate the severe OCD symptoms that had emerged. Following the hormone replacement therapy, the patient experienced a notable decrease in both depression and OCD symptoms. Additionally, she reported an increase in libido, which had been significantly affected post-surgery. Clinical impressions indicated a marked improvement in her overall mental health and quality of life.

The pre- and post-treatment data analysis revealed substantial improvements across several standardized scales used to measure OCD, anxiety, and depression. Specifically, her scores on the Yale-Brown Obsessive-Compulsive Scale (YBOCS) reduced from 39 to 13, indicating a significant reduction in the severity of her OCD symptoms. The Hamilton Anxiety Rating Scale (HAM-A) scores decreased from 23 to 3, and the Hamilton Depression Rating Scale (HAM-D) scores dropped from 34 to 6, reflecting substantial alleviations in anxiety and depression. Additionally, the Fixity of Beliefs score decreased from 7 to 3, the Brown Assessment of Beliefs Scale (BABS) improved from

12 to 1, and the NIMH-Global assessment scores improved from 13-15 to 7-9. The Global Assessment Scale (GAS) scores increased from 40-31 to 90-81, showing a significant enhancement in her overall functioning. The Obsessive-Compulsive Inventory - Short Version (OCI-SV) scores were reduced from 41 to 15, and the Obsessive-Compulsive Disorder Not Otherwise Specified (OCON) frequency/distress scores dropped from 103/104 to 30-32. Additionally, the Fear Survey Schedule scores improved from 67 to 127, and the Willoughby Questionnaire scores increased from 18 to 33.

Case #4: 35-Year-Old Female with Late-Onset OCD

This case study involves a 35-year-old first-generation immigrant female who developed severe OCD symptoms later in life. Previously diagnosed with GAD, her OCD symptoms became significantly severe and were notably exacerbated by her menstrual periods. The patient's obsessions included persistent intrusive thoughts related to food and water, which drove her to engage in compulsions that further increased her anxiety and depression. Additionally, she experienced a notable loss of libido, which further impacted her quality of life.

To address these severe symptoms, the patient underwent an integrative treatment plan that included hormone regulation and psychotherapy. The goal was to stabilize her hormonal levels, particularly those affected by her menstrual cycle, and to provide cognitive-behavioral strategies to manage her OCD.

The pre-treatment assessment revealed high scores on several standardized scales used to measure OCD, anxiety, and depression. Specifically, her Yale-Brown Obsessive-Compulsive Scale (YBOCS) score was recorded at 36, indicating severe OCD symptoms, which decreased to 12 post-treatment. The Hamilton Anxiety Rating Scale (HAM-A) score was 38, reflecting a high level of anxiety, which dropped to 10. The Hamilton Depression Rating Scale (HAM-D) score was 31, showing severe depressive symptoms, which fell to 11. The Fixity of Beliefs score indicated rigidity in obsessive beliefs and improved from 13 to 7, while the Brown Assessment of Beliefs Scale (BABS) suggested a significant level of conviction in her obsessive thoughts, improving from 9 to 5. The NIMH-Global assessment score was 34, indicating overall severe psychiatric symptoms, which improved to 6-8. The Global Assessment Scale (GAS) scores were low at 40-31, indicating impaired overall functioning, which increased to 80-71 post-treatment. The Obsessive-Compulsive Inventory - Short Version (OCI-SV) score was 60, showing high distress from obsessive-compulsive symptoms, which reduced to 11. The Obsessive-Compulsive Disorder Not Otherwise Specified (OCON) frequency/distress scores were 74/70, highlighting severe OCD severity and distress, which decreased to 23/24. The Fear Survey Schedule score was 146, indicating a high level of fear responses, which dropped to 31. Lastly, the Willoughby Questionnaire score was 63, demonstrating significant stress and poor coping mechanisms, which improved to 31. These significant improvements across multiple assessment tools underscore the effectiveness of the combined treatment approach in managing severe OCD symptoms and improving the patient's quality of life.

Discussion

The case studies demonstrate that hormonal imbalances significantly impact OCD symptoms. Each case highlights different hormonal influences on the severity and manifestation of OCD, particularly emphasizing the role of hormonal fluctuations during critical periods such as menstruation, pregnancy, postpartum, and post-surgical hormonal changes. The patients experienced varied obsessions and compulsions, which were notably intensified by their hormonal imbalances. These case studies collectively indicate that addressing these imbalances can lead to substantial improvements in OCD symptoms.

A clear link exists between hormonal imbalances and the severity of OCD symptoms. For instance, in Case #1, the patient with PCOS experienced a marked reduction in OCD symptoms following hormone therapy, indicating the significant role of estrogen and progesterone. In Case #2, the patient's OCD symptoms worsened with menstrual cycles, reflecting the impact of hormonal fluctuations on OCD severity. Similarly, Case #3 showed the emergence of severe OCD symptoms post-hysterectomy, highlighting the critical role of surgical-induced hormonal deficiencies. Case #4 further supports this link, with the patient experiencing exacerbated OCD symptoms during menstrual periods. Hormonal events involving estrogen, androgens, progesterone, melatonin, and cortisol play crucial roles in OCD pathophysiology, as seen in these diverse cases.

Hormone replacement therapy (HRT) has proven effective in reducing OCD symptoms, as evidenced by the significant improvements in the patients' conditions. In Case #1, the combined use of metformin, transdermal estradiol, and vaginal progesterone led to substantial reductions in OCD severity, anxiety, and depression. Case #2 also showed marked improvements with hormone therapy tailored to menstrual cycle regulation and PCOD. Case #3 benefited from subcutaneous estradiol and testosterone pellets, which alleviated OCD symptoms and enhanced overall mental health. Case #4's integrative treatment of hormone regulation and psychotherapy demonstrated significant symptom reduction, underscoring the efficacy of HRT in managing severe OCD symptoms.

The findings align with existing research on hormonal influences in OCD, reinforcing the importance of considering hormonal factors in OCD treatment. Previous studies have shown that hormonal fluctuations can trigger or worsen OCD symptoms, particularly during critical periods like menstruation, pregnancy, and menopause. The case studies presented provide real-world evidence supporting these findings, highlighting the critical role of hormonal regulation in managing OCD.

However, it is important to recognize that while the case studies provide valuable insights, they represent individual experiences and may not capture the full spectrum of hormonal influences on OCD. Future studies should involve larger populations to validate the role of hormonal imbalances in OCD and to explore the variability of responses to hormone-based treatments. Furthermore, we must consider that hormone-based treatments may carry risks such as cardiovascular issues, cancer, and metabolic changes. Comprehensive discussions on the safety and potential adverse effects of hormone therapy are necessary to ensure informed decision-making and to mitigate potential risks.

Conclusion

The case studies presented in this paper highlight the significant role of hormonal imbalances in the onset and severity of OCD symptoms. The detailed examination of four diverse cases demonstrates that addressing these hormonal imbalances through tailored treatment approaches can lead

to substantial improvements in OCD symptomatology. The findings emphasize the need for a comprehensive understanding of hormonal influences in the management of OCD.

The evidence from these case studies underscores the critical importance of incorporating hormonal assessments and targeted hormone therapy into OCD treatment plans. By identifying and addressing hormonal imbalances, clinicians can enhance the effectiveness of traditional OCD treatments, leading to better patient outcomes. This integrated approach not only alleviates OCD symptoms but also improves overall mental health and quality of life for patients.

Future research should focus on conducting large-scale studies to further investigate the efficacy of hormone replacement therapy for OCD. Such studies are essential to validate the findings from these case studies and to generalize the results to broader populations. Additionally, exploring the roles of other hormones, such as growth hormone and pregnenolone, in OCD pathophysiology could provide new insights into potential treatment options. Developing standardized hormone testing protocols for OCD patients will also be crucial in advancing the field and ensuring that hormonal factors are consistently considered in clinical practice. By pursuing these research directions, the medical community can better understand the complex interplay between hormonal imbalances and OCD, ultimately leading to more effective and comprehensive treatment strategies.

Conflict of Interest

The authors have read and approved the final version of the manuscript. The authors have no conflicts of interest to declare.

References

1. Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR. Obsessive-compulsive symptoms in pregnancy and the puerperium: A review of the literature. J Anxiety Disord. 2003;17(4):461-478.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
3. American Psychiatric Association. What Is Obsessive-Compulsive Disorder? Psychiatry.org. Accessed August 13, 2024. https://www.psychiatry.org/patients-families/obsessive-compulsive-disorder/what-is-ocd
4. Bright Futures Treatment Center. OCD Statistics, Facts & Prevalence. Brightfuturesny.com. Accessed August 13, 2024. https://www.brightfuturesny.com/ocd-statistics-facts-prevalence/
5. Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: A review. Harv Rev Psychiatry. 1998;6(3):180-187.
6. Chamberlain SR, Menzies L. Endophenotypes of obsessive-compulsive disorder: rationale, evidence and future potential. Expert Rev Neurother. 2009;9(8):1133-1146.
7. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA. The Brown Assessment of Beliefs Scale: Reliability and validity. Am J Psychiatry. 1998;155(1):102-108.
8. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-771.
9. Fairbrother N, Abramowitz JS. Obsessional thoughts and compulsive behaviors in a sample of pregnant and postpartum women. J Clin Psychol. 2007;63(4):422-433.
10. Fairbrother N, Abramowitz JS. Postpartum obsessive-compulsive disorder: A review. J Anxiety Disord. 2007;21(4):374-384.
11. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2012;15(8):1173-1191.
12. Foa EB, Kozak MJ, Salkovskis PM, Coles ME, Amir N. The validation of a new obsessive-compulsive disorder scale: The Obsessive-Compulsive Inventory. Psychol Assess. 1998;10(3):206-214.
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
14. Green SA, Graham BM. Symptom fluctuation over the menstrual cycle in anxiety disorders, PTSD, and OCD: A systematic review. Arch Womens Ment Health. 2022;25(1):71-85.
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
17. Kancheva R, Hill M, Novák Z, Chrastina J, Hampl R. Neuroactive steroids in periphery and cerebrospinal fluid. Neuroendocrinol Lett. 2011;32(6):203-212.
18. Labad J, et al. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry. 2005;66:428-435.
19. Lazarus RS, Folkman S. Stress, appraisal, and coping. New York, NY: Springer Publishing Company; 1984.
20. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: Reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61-68.
21. Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263-267.
22. National Institute of Mental Health. Obsessive-Compulsive Disorder. NIMH.nih.gov. Accessed August 13, 2024. https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd
23. National Institute of Mental Health. Obsessive-Compulsive Disorder. NIMH.nih.gov. Accessed August 13, 2024. https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd
24. Anxiety and Depression Association of America. Obsessive Compulsive Disorder (OCD). Accessed August 13, 2024. https://adaa.org/understanding-anxiety/obsessive-compulsive-disorder-ocd
25. National Institute of Mental Health. Obsessive Compulsive Disorder (OCD) Among Adults. U.S. Department of Health and Human Services. Accessed August 13, 2024. https://www.nimh.nih.gov/health/statistics/obsessive-compulsive-disorder-ocd
26. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799-812.
27. Pauls DL, Alsobrook JP, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. Am J Psychiatry. 1995;152(1):76-84.
28. Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am. 1998;21(4):659-676.
29. Russell EJ, Fawcett JM, Mazmanian D. Risk of obsessive-compulsive disorder in pregnant and postpartum women. J Clin Psychiatry. 2013;74(4):377-385.
30. Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):563-586.

31. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22-33.
32. Storch EA, Rasmussen SA, Price LH. Development and validation of the Yale-Brown Obsessive-Compulsive Scale–Second Edition. Compr Psychiatry. 2004;45(6):375-383.
33. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining "obsessive beliefs": A review and recommendations for classification. Clin Psychol Rev. 2005;25(7):783-803.
34. Vulink NCC, et al. Female hormones affect symptom severity in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2006;21(3):171-175.
35. World Health Organization. Obsessive-Compulsive Disorder. Accessed August 13, 2024. https://www.who.int/news-room/fact-sheets/detail/obsessive-compulsive-disorder
36. Zai G, Zai CC, Arnold PD. The genetics of obsessive-compulsive disorder. Psychiatr Clin North Am. 2012;35(3):161-178.
37. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013;150(2):384-388.

Appendix

Detailed Assessment Tool Descriptions

Yale-Brown Obsessive-Compulsive Scale (YBOCS): The Yale-Brown Obsessive-Compulsive Scale (YBOCS) is a widely used tool for assessing the severity of OCD symptoms. It consists of 10 items that evaluate the severity of obsessions and compulsions separately, with a total score ranging from 0 to 40. Higher scores indicate more severe OCD symptoms. The YBOCS is divided into two subscales: the Obsession Severity Subscale and the Compulsion Severity Subscale. Each item is rated on a 5-point scale (0-4), assessing the time spent, interference, distress, resistance, and control over obsessions and compulsions. The YBOCS has been validated in numerous studies and is considered the gold standard for OCD severity assessment.

Hamilton Anxiety Rating Scale (HAM-A): The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item scale designed to assess the severity of a patient's anxiety. Each item is scored on a scale from 0 (not present) to 4 (severe), with a total score range of 0 to 56. The HAM-A covers both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Items include anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic (muscular), somatic (sensory), cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. The HAM-A is widely used in clinical and research settings to measure the severity of anxiety symptoms. The Hamilton Depression Rating Scale (HAM-D) is a multiple-item questionnaire used to provide an indication of depression and as a guide to evaluate recovery. Each item on the questionnaire is scored on a 3- or 5-point scale, depending on the item, with higher total scores indicating more severe depression. The HAM-D covers a range of symptoms associated with depression, including mood, guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. The HAM-D is extensively used in both clinical and research settings and has been validated as a reliable measure of depression severity.

Fixity of Beliefs: The Fixity of Beliefs scale assesses the rigidity and inflexibility of obsessive beliefs. It measures how strongly patients hold onto their obsessive thoughts and how resistant they are to change. This scale is particularly useful in understanding the cognitive aspects of OCD and the extent to which patients are entrenched in their obsessive beliefs. It provides insight into the cognitive rigidity that often accompanies OCD and helps tailor cognitive-behavioral interventions to address these entrenched beliefs.

Brown Assessment of Beliefs Scale (BABS): The Brown Assessment of Beliefs Scale (BABS) is used to assess the degree of insight patients have into their obsessive-compulsive beliefs. It evaluates the level of conviction, perception of others' views, and willingness to consider alternative explanations. The BABS consists of 7 items, each rated on a scale from 0 (no impairment) to 4 (severe impairment), and includes areas such as conviction, perception of the problem, explanation of others' views, and willingness to consider that the beliefs might be wrong. The BABS is a valuable tool in distinguishing between patients with good, poor, or absent insight into their OCD-related beliefs, which can significantly impact treatment outcomes.

NIMH-Global: The NIMH-Global scale is a global assessment tool for psychiatric symptoms. It provides a single score that reflects the overall severity of a patient's psychiatric condition. The scale is designed to give a quick overview of the patient's global functioning and psychiatric symptomatology, making it useful for both clinical assessments and research purposes. The NIMH-Global scale is often used in conjunction with other, more specific scales to provide a comprehensive picture of a patient's mental health status.

Global Assessment Scale (GAS): The Global Assessment Scale (GAS) is used to rate the social, occupational, and psychological functioning of individuals. Scores range from 0 (severely impaired) to 100 (extremely high functioning), providing a comprehensive overview of a patient's ability to function in daily life. The GAS assesses how much a patient's symptoms affect their daily activities, relationships, and overall ability to cope with life. It is a broad measure that encompasses various aspects of functioning and is useful for tracking changes over time and the impact of treatment interventions.

Obsessive-Compulsive Inventory - Short Version (OCI-SV): The Obsessive-Compulsive Inventory - Short Version (OCI-SV) is a shorter version of the OCI, designed to quickly assess the severity of OCD symptoms. It includes items that measure the distress associated with obsessions and compulsions. The OCI-SV consists of 18 items, each rated on a 5-point scale from 0 (not at all) to 4 (extremely), covering different types of obsessions and compulsions such as washing, checking, ordering, obsessing, hoarding, and neutralizing. The OCI-SV is validated and widely used for both clinical and research purposes due to its brevity and accuracy in assessing OCD symptoms.

Obsessive-Compulsive Disorder Not Otherwise Specified (OCON): The Obsessive-Compulsive Disorder Not Otherwise Specified (OCON) scale is used to assess OCD symptoms that do not fit neatly into the standard diagnostic categories. It helps in identifying and measuring atypical OCD presentations. This scale is particularly important for capturing the full spectrum of OCD symptoms, including those that might be less common or present differently than traditional OCD symptoms. The OCON scale ensures that all aspects of OCD are thoroughly assessed and addressed in treatment plans.

Fear Survey Schedule: The Fear Survey Schedule measures the extent and types of fears experienced by individuals. It covers a wide range of fear-inducing situations and objects, providing a detailed profile of a patient's specific fears. The scale consists of multiple items, each rated on a scale to indicate the level of fear or avoidance associated with various stimuli. This detailed assessment helps clinicians understand the breadth and depth of a patient's fears, which can be critical for effective treatment planning, especially in patients with comorbid anxiety disorders.

Willoughby Questionnaire: The Willoughby Questionnaire evaluates stress and coping mechanisms. It assesses how individuals respond to stress and the strategies they use to manage it, providing insights into their overall coping ability. The questionnaire covers various aspects of stress response, including emotional, cognitive, and behavioral reactions to stress, as well as the effectiveness of different coping strategies. This comprehensive assessment helps in tailoring interventions to improve stress management and enhance overall mental health.